Eyenovia Cash on Hand 2016-2025 | HYPD
Eyenovia cash on hand from 2016 to 2025. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
Eyenovia Annual Cash on Hand
(Millions of US $) |
| 2024 |
$2 |
| 2023 |
$15 |
| 2022 |
$23 |
| 2021 |
$19 |
| 2020 |
$28 |
| 2019 |
$14 |
| 2018 |
$20 |
| 2017 |
$5 |
| 2016 |
$3 |
| 2015 |
$2 |
Eyenovia Quarterly Cash on Hand
(Millions of US $) |
| 2025-03-31 |
$4 |
| 2024-12-31 |
$2 |
| 2024-09-30 |
$7 |
| 2024-06-30 |
$2 |
| 2024-03-31 |
$8 |
| 2023-12-31 |
$15 |
| 2023-09-30 |
$21 |
| 2023-06-30 |
$17 |
| 2023-03-31 |
$18 |
| 2022-12-31 |
$23 |
| 2022-09-30 |
$25 |
| 2022-06-30 |
$22 |
| 2022-03-31 |
$27 |
| 2021-12-31 |
$19 |
| 2021-09-30 |
$21 |
| 2021-06-30 |
$27 |
| 2021-03-31 |
$25 |
| 2020-12-31 |
$28 |
| 2020-09-30 |
$23 |
| 2020-06-30 |
$10 |
| 2020-03-31 |
$14 |
| 2019-12-31 |
$14 |
| 2019-09-30 |
$18 |
| 2019-06-30 |
$9 |
| 2019-03-31 |
$14 |
| 2018-12-31 |
$20 |
| 2018-09-30 |
$21 |
| 2018-06-30 |
$25 |
| 2018-03-31 |
$28 |
| 2017-12-31 |
$5 |
| 2017-09-30 |
$7 |
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| 2016-09-30 |
|
| 2015-12-31 |
$2 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-BIOMED/GENE |
$0.041B |
$0.000B |
|
Eyenovia, Inc. is a clinical stage biopharmaceutical company which engages in developing therapeutics for the treatment of prominent eye diseases primarily in the United States. Its product portfolio includes MicroProst, MicroStat, MicroTears and MicroPine which are in clinical stage. Eyenovia, Inc. is based in New York.
|
